Broadcom named strategic vendor for Walmart virtualization solutions
DSS Inc. (NYSE:DSS), a ten percent owner of Impact Biomedical Inc. (NASDAQ:IBO), has recently sold a significant portion of its holdings in the pharmaceutical company. IBO, currently trading at $1.52, has seen its stock plummet 54% in the past week, according to InvestingPro data. According to a recent filing, DSS sold a total of 476,620 shares of Impact Biomedical common stock in multiple transactions executed between March 21 and March 27, 2025. These transactions were completed at prices ranging from $2.5011 to $3.3004 per share, amounting to a total sale value of approximately $1,950,928. The company, with a market capitalization of $26.23 million, maintains strong financial health with a current ratio of 2.79, indicating solid liquidity.
The transactions included several sales executed through DSS’s subsidiaries, namely DSS Securities, Inc., DSS Blockchain Security, Inc., and DSS BioHealth Security, Inc. Notably, DSS Securities, Inc. and DSS Blockchain Security, Inc. each sold 166,600 shares at $3.3004 per share. DSS BioHealth Security, Inc. also participated, selling the same number of shares at the same price, while additional sales were made directly by DSS Inc. at varying prices.
Following these transactions, DSS Inc.’s direct and indirect holdings in Impact Biomedical have been adjusted accordingly. These sales reflect DSS Inc.’s strategic financial maneuvers concerning its investment in the life sciences sector. InvestingPro analysis suggests IBO is currently undervalued, with 8 additional key insights available to subscribers.
In other recent news, Impact BioMedical Inc. has announced the acquisition of Celios®, an air purification technology company, in an all-equity deal valued at approximately $1.15 million. This strategic move is part of Impact BioMedical’s efforts to expand its health and wellness portfolio and potentially increase immediate revenue. Celios® is renowned for its advanced air purification systems, which are protected by patents in the U.S. and other countries, providing exclusivity through 2043.
In separate developments, Impact BioMedical experienced a significant surge in its stock price, more than doubling without any disclosed material changes in its business operations. The company stated that it was unaware of any recent developments that could explain the sharp increase in its share value. Despite the unusual market activity, no analyst comments have been provided to clarify the situation.
Impact BioMedical continues to focus on its mission to develop innovative healthcare solutions and remains committed to communicating with investors regarding its stock performance. The company’s recent acquisition and stock price fluctuations highlight its dynamic presence in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.